Rosemary Mazanet, M.D., Ph.D., began advising Columbia Care in 2013. She joined its Scientific Advisory Board as its Chair in 2015 and became its Chief Scientific Officer in 2017.
Rosemary trained in Internal Medicine and Oncology at the Brigham and Women’s Hospital/Dana Farber Cancer Institute before
starting her industry career at Amgen in the early 1990s as the head of Clinical Research. At Amgen, Rosemary was given broad responsibilities as one of the first US trained clinician scientists in her field, where she led multiple successful product development initiatives (4 INDs and sBLAs, one BLA, CE mark and IDE) including FDA panel presentations.
Rosemary moved into public equity in 1998 when she joined Oracle Partners LLC in New York as a General Partner. Since that time, she has been a presence in public and private equity biotech and specialty pharma investments, most recently as a General Partner of Apelles Investment Management. In addition to serving as a life sciences management and investment professional, Rosemary has served as a C-suite executive at several biopharma companies and led development programs ranging from IND submission through NDA approval and commercial launch. Her ability to conceive, articulate and execute strategic development and financial vision in
public and private company environments enables her to guide Columbia Care’s research efforts, including at many of the top national academic sites.
Among the many boards she is on, Rosemary is a Charter Trustee at the University of Pennsylvania School of Medicine and is the Co-Chair of the Leonard Davis Institute Executive Advisory Board at Wharton.